Last reviewed · How we verify

Tacrolimus with steroids minimization

Armando Torres Ramírez · FDA-approved active Small molecule Quality 2/100

Tacrolimus with steroids minimization, marketed by Armando Torres Ramírez, is an immunosuppressive therapy with a key composition patent expiring in 2028. The drug's key strength lies in its mechanism of minimizing steroid use, potentially offering a differentiated treatment option for patients. The primary risk is the lack of reported revenue and key trial results, which may limit its market adoption and competitive positioning.

At a glance

Generic nameTacrolimus with steroids minimization
Also known asSimulect; Dacortin; Prograf/Advagraf; Cellcept/Myfortic.
SponsorArmando Torres Ramírez
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: